MannKind Reports Earnings This Week
MannKind Corporation (NASDAQ:MNKD)
MannKind has been one of my favorite stocks to watch, and this week is likely to prove to be a big week for the stock. The reality is that MannKind has been struggling in the market on a poor pre-launch of Afrezza. However, that is likely to change. Tomorrow before the market opens, MannKind will be providing its earnings report for the quarter. While I don’t think investors will care much about earnings, as we already know that they’re not likely to be great, I think that this report may prove to be a catalyst. The reality is that MannKind recently announced that it had tripled its production capacity of Afrezza. With low sales volume, there’s got to be a big reason for this move, one that I think is likely to be announced through the earnings report. So, keep your eyes peeled because this has the potential to be a major catalyst!
Amarin Could Have A Very Strong Week This Week
Amarin Corporation plc (ADR) (NASDAQ:AMRN)
Amarin Corporation had a great day in the market on Friday as a court ruling sent the stock skyrocketing! The case was between Amarin and the FDA in a fight for the disclosure of unapproved affects of Vascepa to physicians. The court ruled that Amarin may disclose unapproved benefits of Vascepa to physicians, leading to a gain of more than 14% in the market. Here’s what John F. Thero, CEO of AMRN had to say following the court ruling…
“This lawsuit is based on the principle that better informed physicians will make better treatment decisions for their patients… Many physicians are aware of the efficacy data including in FDA-approved labeling for Vascepa but are not aware of efficacy data from the ANCHOR study of Vascepa. FDA has already announced the safety data from both the MARINE and ANCHOR studies in approved Vascepa labeling. Amarin will now be able to communicate efficacy data from ANCHOR and other relevant study results to these physicians and to others in the medical community in the context of appropriate disclaimers.”
Considering the reason for the climb, I don’t think we’ve seen the end of it. So, keep a close eye on AMRN throughout the week for opportunities.
Gilead Sciences (GILD) Is Likely To See Strong Growth
Gilead Sciences, Inc. (NASDAQ:GILD)
Finally, we have Gilead Sciences. In my opinion, GILD is one of the strongest stocks in biotech, and for good reason. Even in the face of strong competition, the company has proven its ability to maintain control over the HCV market and recently, they’ve been given a credit rating of A+! However, we saw declines in the stock on Thursday that have brought it down to support followed by relatively flat movement on Friday. Therefore, I’m expecting to see strong gains from GILD throughout the week.